This study is testing a new medicine, adagrasib, for patients with a type of lung cancer called NSCLC (Non-Small Cell Lung Cancer) that has a KRAS G12C mutation. This mutation is a specific change in the cancer's DNA. The study has two phases. Phase 2 looks at how well adagrasib works alone or with another medicine called pembrolizumab (Keytruda®). Pembrolizumab helps the immune system fight cancer. Patients in Phase 2 have cancer that can't be removed by surgery or has spread. Phase 3 compares the combination of adagrasib and pembrolizumab to pembrolizumab alone. Patients need a PD-L1 TPS score of 50% or higher for Phase 3. This score shows how much of a protein is on the cancer cells.

• Study involves two phases, with different treatments and eligibility criteria.
• Participants must not have had prior treatment for advanced lung cancer.
• Compensation and treatment details will be provided upon enrollment.